Igor Sill

Igor Sill is an accomplished investor with extensive experience in venture capital and early-stage investments across various sectors. Currently, Igor serves as a Seed Investor at Cereus Biosciences, focused on developing universal cancer vaccines, and as an LP Investor in SHAKTI Titan fund, leveraging a network of innovative founders. Previous roles include Direct Investor at VantIQ, seeking advancements in AI applications, and Seed Investor at Foghorn Therapeutics, which specializes in oncology medications. As one of the initial seed investors in Salesforce, Igor has a strong history in supporting tech startups, alongside previous executive roles at Geneva Venture Partners and Geneva Group International, emphasizing investment strategy, executive recruitment, and supporting startups to IPO. Igor's education includes multiple MBA degrees from esteemed institutions such as the University of Oxford and Harvard Business School, along with training in venture capital and financial markets.